Immunebridge

Developer of allogeneic cellular medicines to treat cancer

placeSan Francisco, California, United States calendar_todayFounded 2018 groups4 employees language immunebridge.com

Registered entities

Social engagement

Social engagement: 4.2K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

10 investors on record; lead investors include Insight Partners, M Ventures, NFX.

Investor typeCountShare
Venture capital880%
Private equity110%
Angel & family office110%

Recent activity

17 Mar 2026
Event
Innate Killer Summit
Coming soon